Drugs / PCAR-019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02819583 | Oct 2016 → Sep 2018 | B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma +1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02851589 | Jul 2016 → Nov 2018 | B-cell prolymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCAR-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02851589 ↗ |
| Modality | Cell therapy | “CAR-T cell immunotherapy” NCT02819583 ↗ |
| Route | Other | “by infusion” NCT02819583 ↗ |
| Target | CD19 | “targeting CD19 antigen” NCT02819583 ↗ |